SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

DraftKings, Inc. is a digital sports entertainment and gaming company, which engages in the provision of online sports betting, online casino, daily fantasy sports product offerings, DraftKings Marketplace, retail sportsbook, media, and other consumer product offerings. The company was founded by Jason D. Robins, Matthew Kalish, and Paul Liberman on December 31, 2011 and is headquartered in Boston, MA.

DraftKings Inc. - Ordinary Shares - Class A

DraftKings Inc

DraftKings is facing intense downward pressure driven by concerns over mounting legal challenges, including a lawsuit from the NCAA, and broader industry debates surrounding the regulation of prediction markets. Investors are actively debating the stock's future, with many on community forums expressing bearish sentiment and a preference for shorting the shares amid ongoing insider selling and heightened competition.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Charles Schwab is facing a wave of intense backlash from users following widespread platform outages and persistent trading restrictions, with the community actively debating whether these failures point to systemic infrastructure weaknesses. Amidst these technical frustrations, users are increasingly discussing legal avenues and comparing the platform to competitors like Interactive Brokers and Robinhood, while some investors monitor how these service disruptions impact the firm's overall market standing.

Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980, and is headquartered in Cambridge, MA.

Sarepta Therapeutics Inc

Sarepta Therapeutics is trending as investors react to the release of preliminary clinical data from its new siRNA pipeline targeting FSHD1 and DM1, which has fueled a strong rally and renewed discussions about the company's long-term growth prospects beyond its core DMD franchise. The stock's performance is further energized by active community speculation regarding a potential short squeeze and conflicting views on the company's valuation compared to peers, keeping sentiment highly charged.

Mask Network is the core product of Dimension, which is positioned to become the bridge that connects internet users from Web 2.0 to Web 3.0. The foundational technology of Mask Network is a peer-to-peer encrypted messaging application, with new functions continuously being created around this foundation. We at Mask Network are strong believers in the ownership economy. People should own what they produce, people should own their data, their attention and the virtual space they choose to contribute to.  Mask Network integrates decentralized social messaging, borderless payment network, and decentralized file storage and sharing to provide a safe and convenient portal for users to jump right into the continent of decentralized finance and then the new world of Web 3.0.

Mask Network

Mask Network is trending as investors capitalize on its extreme low-float status following a recent reverse split, sparking comparisons to historical micro-cap runners. The community is actively monitoring technical setups and liquidity for potential momentum swings, while enthusiasm remains high regarding its position in the AI and Web3 infrastructure space.

Journey Medical Corp. is a commercial-stage pharmaceutical company, which focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions. Its brands include QBREXZA, Accutane, Targadox, AMZEEQ, Ximino, ZILXI, Exelderm, and Luxamend. The company was founded by Claude Maraoui in October 2014 and is headquartered in Scottsdale, AZ.

Journey Medical Corp

Journey Medical Corp is experiencing high community interest following the FDA approval of Emrosi, with investors keenly focused on the upcoming commercialization strategy and potential for profitability in 2025. Discussion is currently centered on insurance coverage expectations, the upcoming commercialization conference call, and the belief that the stock is undervalued given its potential to capture significant market share from existing rosacea treatments.

Destiny Tech100, Inc. operates as a non-diversified, closed-end management investment company. The company was founded on November 18, 2020 and is headquartered in Austin, TX.

Destiny Tech100 Inc

DESTINY TECH 100 INC

Destiny Tech100 is drawing significant attention from retail traders who view it as a strategic proxy for high-profile private companies like SpaceX and OpenAI ahead of potential IPO activity. The community is actively debating the fund's premium-to-NAV volatility, with many traders framing it as a squeeze candidate due to its small float while weighing it against other SpaceX-exposed alternatives like SATS and VCX.

Karman Holdings, Inc. engages in the design, testing, manufacturing, and sale of dependable missile systems. It offers Payload Protection & Deployment Systems, Aerodynamic Interstage Systems, and Propulsion Systems. The company was founded on August 20, 2020 and is headquartered in Huntington Beach, CA.

Karman Holdings Inc.

Karman Holdings Ord Shs

Karman Holdings is generating significant interest after reporting strong quarterly results and raising its revenue and EBITDA guidance, fueling optimism around its role in hypersonic defense and the munitions "super cycle." While some investors express caution regarding the stock's valuation and the impact of its recent expansion through acquisitions, the community remains bullish on its long-term fundamentals and potential as a critical player in national defense.

ORCASM is a filthy little memecoin that knows exactly what you came for. It launched on Orca's Wavebreak but was born to make waves—wet, loud, and unforgettable. This isn’t your ordinary meme. ORCASM builds up the tension slow, goes deep, and leaves you gasping for more. It’s raw, unfiltered trencher energy dripping with shameless satisfaction. No promises. No roadmaps. Just pure, orcasmic pleasure.

Orcasm

Orcasm is attracting significant attention as part of a broader shift toward marine-themed meme coins, with community members actively discussing its market volatility and the potential for rapid gains. Discussions are heavily focused on navigating whale movements, managing potential pump-and-dump risks, and debating the sustainability of this trending speculative asset.

On Holding AG engages in the development and distribution of sports products such as footwear, apparel, and accessories for high-performance running, outdoor, all-day activities, and tennis. It sells its products worldwide through independent retailers and global distributors, its own online presence, and its own stores. The company was founded by David Allemann, Olivier Bernhard, and Caspar Coppetti in January 2010 and is headquartered in Zurich, Switzerland.

On Holding AG - Ordinary Shares Class A

On Holding AG

On Holding is experiencing significant volatility as the market reacts to the surprise resignation of CEO Martin Hoffmann and the transition to a co-CEO structure led by the company's founders. Investors and the community remain deeply divided, with some viewing the leadership shake-up as a concerning sign of instability, while others see the return of the founders as a positive catalyst to reignite innovation and long-term brand growth.

Navan, Inc. engages in offering a cloud-based technology platform for travelers. Its products include business travel and expense management. The company was founded by Ariel Cohen and Ilan Twig in February 2015 and is headquartered in Palo Alto, CA.

Navan Inc. - Ordinary Shares - Class A

Navan shares are experiencing high volatility as investors weigh strong revenue growth and AI platform integration against concerns regarding profitability and recent insider selling. While some community members view the stock as a long-term play on travel disruption, others remain skeptical about its valuation and post-IPO performance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Wells Fargo cut Doximity’s price target to $45 from $55 while maintaining an ‘Overweight’ rating.</li><li>Piper Sandler expressed confidence in Doximity’s platform despite a bleak near-term outlook.</li><li>The&nbsp;company expects Q4 revenue in the range of $143 million to $144 million, compared to $185.1 million it reported in the third quarter.</li></ul>Shares of Doximity Inc. (DOCS) slumped 35% in premarket trading on Friday, following a series of brokerage actions amid regulatory pressures and lower-than-expected fourth-quarter revenue guidance.If the pre-market levels hold after the opening bell, <a href="https://stocktwits.com/symbol/DOCS">DOCS stock </a>will fall to its lowest levels since November 2023.<h2 class="st-heading-2">Competition, Regulatory Pressure Are Key Risks</h2>Wells Fargo cut Doximity’s price target to $45 from $55 while maintaining an ‘Overweight’ rating, according to The Fly. The firm said limited visibility was already a concern ahead of the third quarter, but additional caution from pharmaceutical clients led to fewer upfront commitments and slower conversions than expected. While the stock’s decline to around $20 appears excessive, the brokerage noted that investor sentiment could take time to reboundPiper Sandler slashed the company’s price target to $40 from $70, while maintaining an ‘Overweight’ rating. Analyst Jessica Tassan noted that Doximity is off to a slow start in 2026, with weak Q2 and Q3 bookings, as market growth slowed to about 5% and sales cycles lengthened amid pharma’s macro-driven caution. Despite the bleak near-term outlook, the firm expressed confidence in Doximity’s platform's strength.Needham analyst Scott Berg lowered Doximity’s price target to $55 from $75 while maintaining a ‘Buy’ rating, citing competition and regulatory pressures as key risks even if the sell-off appears overdone. Although the Q4 guidance is disappointing, Needham expects budgets to improve through 2026.<h2 class="st-heading-2">Client Uncertainty Around Policy Changes</h2>In a call with analysts on Thursday, Doximity stated that client uncertainty around recent policy changes and the Most Favored Nation agreement affected its annual budgets.“First, we saw multiple customers deploy a lower percentage of their annual budgets upfront than usual as 2026 planning wasn't fully complete and some funds remained unreleased,” said Timothy Cabral, a member of the board.“Second, this uncertainty resulted in many deals we normally have signed by December 31 being delayed and pushed into our fiscal Q4. This is evident in our January pharma bookings growth rate, which is the best we've seen since going public,” Cabral added.Doximity’s Q3 revenue grew 10% to $185.1 million, but its diluted earnings per share declined to $0.31 from $0.37. The company expects Q4 revenue in the range of $143 million to $144 million and FY 2026 revenue between $642.5 million and $643.5 million. The company also announced a share repurchase program of up to $500 million of its Class A common stock.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>Despite the pre-market crash, retail sentiment flipped to “extremely bullish” from “bearish” over the past 24 hours, amid “extremely high” message volumes.<img src="https://news.stocktwits-cdn.com/DOCS_jpg_2d9473084f.webp" alt="DOCS.jpg">Users felt that the selloff was an “overreaction”.<stembedurl>https://stocktwits.com/Noisy/message/644244636</stembedurl><stembedurl>https://stocktwits.com/giuseppe8469/message/644205757</stembedurl>Over the past year, the stock has declined by around 43%.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/amzn-stock-falls-below-long-term-moving-average-slumps-premarket/cZbFfDJR4nC">AMZN Stock Falls To 8-Month Lows In Pre-Market After Declining Below 200-DMA For First Time Since October</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

S&P 500 Index trades listlessly ahead of Nvidia earnings. 

Why Did DOCS Stock Plunge 35% In Pre-Market Today?

Multiple brokerages cut their price target on the stock after Doximity reported a fall in third-quarter earnings and a soft fourth-quarter revenue outlook.

UMDD
ProShares UltraPro MidCap400

Feed

News

Sentiment

Fundamentals

Info

Latest UMDD News

UMDDProShares UltraPro MidCap400